Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib Target Occupancy in Healthy Adults
NCT05128058Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ritlecitinib tosilate in alopecia areata (2 cohorts), sponsored by Pfizer. Primary endpoints: Percent Target Occupancy for JAK3 at 48 hours, Percent Target Occupancy for BTK at 48 hours and 4 more. Started Oct 2021; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05128058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128058.